Drug Type CAR-T  | 
Synonyms Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22(Tongji Hospital Tongji Medical College of HUST), Targeting CD19 and CD22 with CAR-T cells(Tongji Hospital Tongji Medical College of HUST)  | 
Target  | 
Action modulators  | 
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators)  | 
Therapeutic Areas  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhaseEarly Phase 1  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Burkitt Lymphoma | Phase 1 | - | 15 Mar 2025 | |
| Pre B-cell acute lymphoblastic leukemia | Phase 1 | - | 15 Mar 2025 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | - | 15 Mar 2025 | 





